rtensionHypertension, or high blood pressure, is a chronic medical condition in which blood pressure is elevated at levels of 140 mm Hg or greater systolic or 90 mm Hg or greater diastolic. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Hypertension impacts approximately 75 million Americans, or nearly one in three adults. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. Hypertension typically has no symptoms.
Adults of all ages and backgrounds can develop hypertension; however, the risk of developing the condition increases with age, with more than half of people over age 60 affected. Hypertension is also costly to the nation's health care system. The American Heart Association recently estimated that direct and indirect expenses associated with hypertension cost the nation more than $73 billion in 2009.
About EDARBI Developed by Takeda, EDARBI is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension to lower blood pressure in adults. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. There are no controlled trials demonstrating risk reduction with EDARBI. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.
EDARBI may be used either alone or in combination with other antihypertensive agents. The recommended dose of EDARBI in adults is 80 mg taken once daily. A starti
Page: 1 2 3 4 5 Related medicine technology :1
|SOURCE Takeda Pharmaceuticals North America, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. FDA Approves Edarbi to Treat High Blood Pressure2
. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension3
. The Next Generation in Bilevel Therapy Now Available on ResMeds Award-Winning S9™ Platform4
. Affordable Nerve Pain Treatment Now Available in the U.S.5
. ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S.6
. Axiron® (Testosterone) Topical Solution CIII Now Available in Pharmacies7
. Songbird® Hearing Launches the Worlds First High-Quality, Low-Cost Sound Enhancement Product Available at Retail8
. New Acetadote® Formulation Now Available in the U.S.9
. Video from Novo Nordisk A/S available on thenewsmarket.com: Novo Nordisk Receives Approval for Victoza in China10
. Allon Therapeutics CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com11
. Delta National Excellence in Therapy Report Now Available